Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma

A small percentage of patients have multiple synchronous primary cancers at presentation. In the last five years, many regimens associated with immunotherapy and chemotherapy were approved for first-line metastatic non-small-cell lung cancer (NSCLC) and other solid tumors, but the study of immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, Diogo, Mambetsariev, Isa, Fricke, Jeremy, Schmolze, Daniel, Afkhami, Michelle, Mannan, Rifat, Kim, Pauline, Therese Dingal, Shaira, Nguyen, Bao, Babikian, Razmig, Fong, Yuman, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2023
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240843/
https://www.ncbi.nlm.nih.gov/pubmed/37160318
http://dx.doi.org/10.1101/mcs.a006262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240843/
https://www.ncbi.nlm.nih.gov/pubmed/37160318
http://dx.doi.org/10.1101/mcs.a006262

Ejemplares similares